#BiTAC
VERAXA Biotech presents at #PEGSEurope 2026 in Lisbon, 16-19 Nov. Four sessions on superior tumor selectivity: BiTAC-TCE (VXA-102 talk, Tue 17 Nov 9:00 WET; poster A111) and a bispecific ADC (VXA-221 talk, Wed 18 Nov 19:00 WET; poster B117). Book a meeting. #BiTAC #ADCs
November 9, 2026 at 2:54 PM
VERAXA Biotech (NASDAQ: VRXA) is adopting FDA-aligned New Approach Methodologies to advance its BiTAC cancer pipeline, cutting animal use dramatically while generating more human-relevant preclinical data. #Oncology #Biotech
November 3, 2026 at 7:13 PM
VERAXA Biotech (NASDAQ: VRXA) is advancing its BiTAC platform, designed to activate cancer-killing activity only when two molecules recognize targets on the same tumor cell. Preclinical results show improved safety and comparable efficacy to conventional therapies. #Oncology #Biotech
November 3, 2026 at 6:57 PM
VERAXA Biotech (NASDAQ: VRXA) unveiled first in vivo data showing significant tumor regression from its BiTAC-ADC platform at the World ADC Congress — with no body weight loss and a promising safety profile. A potential step forward in targeted cancer therapy. #Oncology #Biotech
October 14, 2026 at 9:20 PM
VERAXA Biotech (NASDAQ: VRXA) unveiled first in vivo data showing tumor regression in breast cancer models using its BiTAC-ADC platform — with no body weight loss observed. Early results suggest strong efficacy and improved safety vs. conventional ADCs. #Oncology #Biotech
October 13, 2026 at 9:10 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global capital markets expertise as the company advances its BiTAC oncology platform, including antibody-drug conjugates and T-cell engagers. #Biotech #Oncology
October 9, 2026 at 6:56 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global capital markets expertise as the company advances its BiTAC oncology platform, including antibody-drug conjugates and T-cell engagers. #Biotech #Oncology
October 9, 2026 at 6:56 PM
VERAXA Biotech (NASDAQ: VRXA) debuts on U.S. markets with its precision 'AND-gated' BiTAC cancer platform, early preclinical proof of concept, $27.5M in financing, and two key executive hires. A Swiss biotech to watch. #Oncology #Biotech
October 9, 2026 at 6:43 PM
VERAXA Biotech (NASDAQ: VRXA) is advancing its 'AND-gated' BiTAC cancer platform following its NASDAQ debut in June 2026. Early preclinical data and key leadership hires signal the Swiss biotech is gaining momentum in oncology drug development. #Oncology #Biotech
October 9, 2026 at 6:25 PM
Heading to the 17th World ADC San Diego Summit, Oct 12-15! $VERAXA’s Dr. Christoph Erkel, CSO, and Dr. Paul Sauter, Senior Director ADC Tech & Chemistry, will be on-site to share how we're building on our BiTAC® platform to shape what’s next in #ADC design. Stay tuned for more!
October 8, 2026 at 12:13 PM
thyssenkrupp nucera secures another chlor-alkali win in China — Hongniu Lanzhou's first-ever entry into the sector, built on nucera's e-BiTAC v7 technology in Northwest China.

Steady orders in a volatile market. Full story:

fcw.sh/04OOoW

#Electrolysis #ChlorAlkali #ChinaEnergy
September 29, 2026 at 3:24 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Dr. Christoph Erkel as CSO to advance its proprietary BiTAC T cell engager platform toward clinical development. Preclinical data at AACR showed promising selective cancer cell activity. #Oncology #Biotech
September 10, 2026 at 8:00 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global finance expertise to accelerate its next-gen cancer therapy pipeline and proprietary BiTAC platform. #Biotech #Oncology
September 8, 2026 at 8:01 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global finance experience to support its capital strategy and BiTAC cancer therapy platform. #Biotech #Oncology
September 4, 2026 at 8:03 PM
We’re delighted to welcome Raju Willener, MBA, MA, as our new Chief Financial Officer! His strategic expertise will help advance our BiTAC® platform and shift our pipeline toward the clinic.

For more see: bit.ly/3Tb45pK

#$VRXA #Biotech #ADCs #TCEs
September 4, 2026 at 12:30 PM
VERAXA Biotech (NASDAQ: VRXA) advances its dual-targeting BiTAC cancer platform, with its lead T-cell engager nearing IND-enabling studies and VXA-222 bispecific ADC moving past discovery. 50+ patents support a growing oncology pipeline. #Oncology #Biotech
August 27, 2026 at 11:18 AM
VERAXA Biotech (NASDAQ: VRXA) receives favorable regulatory guidance from Germany's Paul-Ehrlich-Institute for its lead BiTAC-TCE cancer therapy, potentially clearing the path toward clinical trials. Preclinical data showed selective dual-biomarker cancer cell targeting. #Oncology #Biotech
August 27, 2026 at 11:13 AM
VERAXA Biotech (NASDAQ: VRXA) advances its VXA-222 cancer program beyond discovery, filing first patents on its BiTAC platforms while building a diversified oncology pipeline of bispecific antibodies and ADCs. #Oncology #Biotech
August 27, 2026 at 11:13 AM
VERAXA Biotech (NASDAQ: VRXA) is advancing its BiTAC platform in antibody-drug conjugates and T-cell engagers, two areas drawing massive pharma investment. Its pipeline targets future partnerships, licensing deals, and asset transactions. #Biotech #AntibodyTherapeutics
August 7, 2026 at 8:01 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Dr. Christoph Erkel as Chief Scientific Officer to lead its BiTAC cancer therapy platform toward clinical development. Recent regulatory clarity from Germany's Paul-Ehrlich-Institute adds momentum to its lead oncology program. #Biotech #Oncology
July 30, 2026 at 8:01 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Dr. Christoph Erkel as Chief Scientific Officer to lead its BiTAC cancer therapy platform toward clinical development. Recent regulatory clarity from Germany's Paul-Ehrlich-Institute adds momentum to the pipeline. #Biotech #Oncology
July 29, 2026 at 11:02 PM
VERAXA Biotech (NASDAQ: VRXA) now holds 50+ patents across 14 countries protecting its next-gen BiTAC cancer therapy platforms, with core technology protection expected through at least 2047. #Oncology #Biotech
July 29, 2026 at 11:01 PM